Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia

Tumor Biology

Volumn 28, Issue 6, 2007, Pages 318-326

  Shabani, Mahdi ^a   Asgarian Omran, Hossein ^a   Jeddi Tehrani, Mahmood ^b,e   Vossough, Parvaneh ^c   Faranoush, Mohammad ^c   Sharifian, Ramazan A ^a   Toughe, Gholam R ^a   Kordmahin, Mahin ^a   Khoshnoodi, Jalal ^a   Roohi, Azam ^a   Tavoosi, Narjes ^b   Mellstedt, Hakan ^e   Rabbani, Hodjatallah ^b,e   Shokri, Fazel ^a,b,d  

^a UNIVERSITY OF TEHRAN   (Iran)

^b Avesina Research Institute   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Immunophenotype; Receptor tyrosine kinase; Ror1; RT PCR; Tumor associated antigen

Indexed keywords

MESSENGER RNA; MITOGENIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN TYROSINE KINASE; TUMOR ANTIGEN; TYROSINE KINASE ROR1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL ISOLATION; CELL LINE; CELL STIMULATION; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IRAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; POKEWEED; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 42449110211     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121405     Document Type: Article

References (37)

1. Ko EC, Wang X, Ferrone S: Immunotherapy of malignant diseases: Int Arch Allergy Immunol 2003;132:294-309.
2. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
3. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19:1416-1423.
4. Jimeno A, Hidalgo M: Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol 2005;53:179-192.
5. Bennasroune A, Gardinl A, Aunis D, Crémel G, Hubert P: Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004;50:23-38.
6. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-315.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sandersanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
8. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
9. Reilly JT: Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev 2003;17:241-248.
10. Gupta R, Knight CL, Bain BJ: Receptor tyrosine kinase mutations in myeloid neoplasms. Br J Haematol 2002;117:489-508.
11. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
12. Forrester WC, Dell M, Perens E, Garriga GA: C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 1999;400:881-885.
13. Oishi I, Sugiyama S, Liu ZJ, Yamamura H, Nishida Y, Minami Y: A novel Drosophila receptor tyrosine kinase expressed specifically in the nervous system. Unique structural features and implication in developmental signaling. J Biol Chem 1997;272:11916-11923.
14. Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, Liu ZJ, Hatta T, Akira S, Matsuda Y, Yamamura H, Otani H, Minami Y: Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 1999;4:41-56.
15. Masiakowski P, Carroll RD: A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992;267:26181-26190.
16. Reddy UR, Phatak S, Allen C, Nycum LM, Sulman EP, White PS, Biegel JA: Localization of the human Ror1 gene (NTRKR1) to chromosome 1p31-p32 by fluorescence in situ hybridization and somatic cell hybrid analysis. Genomics 1997;41:283-285.
17. Reddy UR, Phatak S, Pleasure D: Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 1996;13:1555-1559.
18. Glass DJ, DeChiara TM, Stitt TN, DiStefano PS, Valenzuela DM, Yancopoulos GD: The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Cold Spring Harb Symp Quant Biol 1996;61:435-444.
19. Wilson C, Goberdhan DC, Steller H: Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc Natl Acad Sci USA 1993;90:7109-7113.
20. Forrester WC, Perens E, Zallen JA, Garriga G: Identification of Caenorhabditis elegans genes required for neuronal differentiation and migration. Genetics 1998;148:151-165.
21. Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, Itoh K, Tamura S, Ueda T, Hatta T, Otani H, Terashima T, Takada S, Yamamura H, Akira S, Minami Y: Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 2000;5:71-78.
22. Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, Takada S, Minami Y: Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev 2001;105:153-156.
23. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, Kitamura M, Itoh K, Takeuchi S, Takeda K, Akira S, Ikeya M, Takada S, Minami Y: Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 2001;21:8329-8335.
24. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638.
25. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
26. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vosoogh P, Faranoush M, Sharifian RA, Jeddi-Tehrani M, Rabbani H, Shokri F: Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol 2007;4:15-25.
27. Rezvany MR, Jeddi-Tehrani M, Rabbani H, Lewin N, Avila-Cariño J, Österborg A, Wigzell H, Mellstedt H: Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000;111:608-617.
28. Shibuya H, Nagai T, Ishii A, Yamamoto Y, Hirohata S: Differential regulation of Th1 responses and CD154 expression in human CD4+ T cells by IFN-α. Clin Exp Immunol 2003;132:216-224.
29. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
30. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP: Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 1998;18:109-119.
31. Herbst RS, Langer CJ: Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:27-36.
32. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;24:674-679.
33. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
34. Fukuda T, Lu D, Carson DA, Kipps TJ: Restricted expression of the orphan tyrosine kinase receptor ROR1 in chronic lymphocytic leukemia. Blood 2004;104, ASH Meeting Abstracts.
35. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Buchner T, Brandts C, Berdel WE, Serve H: High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 2004;10:1241-1249.
36. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
37. Sell S: Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007;3:1-6.